Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$309.70 -0.8%	$277.63	$205.87 ▼ $317.54	$40.38B	0.22	929,711 shs	1.34 million shs
BMRN BioMarin Pharmaceutical	$55.00 -0.4%	$58.88	$52.93 ▼ $94.85	$10.55B	0.19	1.72 million shs	4.71 million shs
HZNP Horizon Therapeutics Public	$116.30	$115.72	$60.03 ▼ $116.38	$26.63B	1.03	2.50 million shs	N/A
RPRX Royalty Pharma	$34.86 -0.1%	$33.14	$24.05 ▼ $35.38	$19.60B	0.48	3.65 million shs	5.35 million shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	0.00%	+0.56%	+7.16%	+9.30%	+101.29%
BMRN BioMarin Pharmaceutical	0.00%	-2.17%	-5.19%	-22.80%	-34.64%
HZNP Horizon Therapeutics Public	0.00%	0.00%	0.00%	0.00%	0.00%
RPRX Royalty Pharma	0.00%	+0.06%	+7.89%	+3.44%	+32.75%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALNY Alnylam Pharmaceuticals	4.0523 of 5 stars	2.4	5.0	0.0	4.3	2.0	2.5	0.6
BMRN BioMarin Pharmaceutical	4.9619 of 5 stars	3.4	5.0	0.0	3.3	2.7	2.5	4.4
HZNP Horizon Therapeutics Public	1.1388 of 5 stars	0.0	0.0	0.0	3.2	0.6	1.7	1.9
RPRX Royalty Pharma	4.8324 of 5 stars	3.6	1.0	3.3	3.7	3.5	1.7	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.77	Moderate Buy	$319.58	3.19% Upside
BMRN BioMarin Pharmaceutical	2.74	Moderate Buy	$93.45	69.92% Upside
HZNP Horizon Therapeutics Public	0.00	N/A	N/A	N/A
RPRX Royalty Pharma	3.25	Buy	$47.33	35.78% Upside

Current Analyst Ratings Breakdown

Latest ALNY, HZNP, BMRN, and RPRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	ALNY Alnylam Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$330.00 ➝ $338.00
5/16/2025	RPRX Royalty Pharma	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$51.00
5/5/2025	BMRN BioMarin Pharmaceutical	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$124.00 ➝ $104.00
5/2/2025	ALNY Alnylam Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$331.00 ➝ $349.00
5/2/2025	ALNY Alnylam Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$300.00 ➝ $325.00
5/2/2025	BMRN BioMarin Pharmaceutical	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$82.00 ➝ $78.00
4/11/2025	ALNY Alnylam Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$284.00 ➝ $268.00
4/9/2025	ALNY Alnylam Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$320.00 ➝ $320.00
4/2/2025	ALNY Alnylam Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$500.00 ➝ $500.00
3/31/2025	ALNY Alnylam Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$338.00 ➝ $342.00
3/31/2025	ALNY Alnylam Pharmaceuticals	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$353.00

(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$2.25B	17.96	N/A	N/A	$0.52 per share	595.58
BMRN BioMarin Pharmaceutical	$2.85B	3.70	$3.25 per share	16.94	$29.69 per share	1.85
HZNP Horizon Therapeutics Public	$3.63B	7.34	$7.05 per share	16.49	$22.38 per share	5.20
RPRX Royalty Pharma	$2.26B	8.66	$4.19 per share	8.31	$17.56 per share	1.99

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	-$278.16M	-$2.09	N/A	347.98	N/A	-11.49%	-510.31%	-6.48%	7/30/2025 (Estimated)
BMRN BioMarin Pharmaceutical	$426.86M	$2.69	20.45	12.61	0.75	17.76%	11.34%	8.95%	8/4/2025 (Estimated)
HZNP Horizon Therapeutics Public	$521.48M	$1.87	62.19	20.55	3.96	12.02%	20.46%	11.52%	N/A
RPRX Royalty Pharma	$858.98M	$1.85	18.84	7.17	1.79	48.23%	24.71%	13.87%	8/6/2025 (Estimated)

Latest ALNY, HZNP, BMRN, and RPRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/8/2025	Q1 2025	RPRX Royalty Pharma	$0.99	$1.06	+$0.07	$0.41	$724.69 million	$839.00 million
5/1/2025	Q1 2025	ALNY Alnylam Pharmaceuticals	-$0.37	-$0.44	-$0.07	-$0.44	$584.32 million	$594.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BMRN BioMarin Pharmaceutical	N/A	N/A	N/A	N/A	N/A
HZNP Horizon Therapeutics Public	N/A	N/A	N/A	N/A	N/A
RPRX Royalty Pharma	$0.88	2.52%	N/A	47.57%	5 Years

Latest ALNY, HZNP, BMRN, and RPRX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/21/2025	RPRX Royalty Pharma	quarterly	$0.22	2.7%	5/16/2025	5/16/2025	6/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	8.88	3.04	2.98
BMRN BioMarin Pharmaceutical	0.10	5.52	3.49
HZNP Horizon Therapeutics Public	0.48	4.27	4.09
RPRX Royalty Pharma	0.68	1.56	1.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
BMRN BioMarin Pharmaceutical	98.71%
HZNP Horizon Therapeutics Public	80.37%
RPRX Royalty Pharma	54.35%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	1.20%
BMRN BioMarin Pharmaceutical	0.85%
HZNP Horizon Therapeutics Public	2.20%
RPRX Royalty Pharma	18.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,230	130.39 million	128.82 million	Optionable
BMRN BioMarin Pharmaceutical	3,040	191.78 million	190.15 million	Optionable
HZNP Horizon Therapeutics Public	2,115	228.99 million	223.96 million	Optionable
RPRX Royalty Pharma	80	562.24 million	455.98 million	Optionable

ALNY, HZNP, BMRN, and RPRX Headlines

Recent News About These Companies

Yousif Capital Management LLC Acquires New Holdings in Royalty Pharma PLC (NASDAQ:RPRX)

June 22 at 3:12 AM | marketbeat.com

Royalty Pharma (NASDAQ:RPRX) Rating Increased to Buy at Wall Street Zen

June 22 at 2:25 AM | americanbankingnews.com

Royalty Pharma (NASDAQ:RPRX) Upgraded by Wall Street Zen to "Buy" Rating

June 21 at 2:54 AM | marketbeat.com

Advisor Resource Council Purchases New Position in Royalty Pharma PLC (NASDAQ:RPRX)

June 20 at 7:36 AM | marketbeat.com

How Is The Market Feeling About Royalty Pharma?

June 19 at 1:16 PM | benzinga.com

Wealth Enhancement Advisory Services LLC Takes Position in Royalty Pharma plc (NASDAQ:RPRX)

June 17, 2025 | marketbeat.com

Short Interest in Royalty Pharma plc (NASDAQ:RPRX) Grows By 39.9%

June 16, 2025 | marketbeat.com

Bank Pictet & Cie Europe AG Sells 10,000 Shares of Royalty Pharma plc (NASDAQ:RPRX)

June 16, 2025 | marketbeat.com

53,487 Shares in Royalty Pharma plc (NASDAQ:RPRX) Bought by SG Americas Securities LLC

June 16, 2025 | marketbeat.com

Merit Financial Group LLC Invests $252,000 in Royalty Pharma plc (NASDAQ:RPRX)

June 13, 2025 | marketbeat.com

GAMMA Investing LLC Buys 77,751 Shares of Royalty Pharma plc (NASDAQ:RPRX)

June 13, 2025 | marketbeat.com

Royalty Pharma (NASDAQ:RPRX) Reaches New 52-Week High - Here's Why

June 12, 2025 | marketbeat.com

Handelsbanken Fonder AB Decreases Stock Position in Royalty Pharma plc (NASDAQ:RPRX)

June 12, 2025 | marketbeat.com

RPRX Q1 Earnings Call: Flat Revenue, Portfolio Expansion, and Capital Return Initiatives

June 10, 2025 | msn.com

Pallas Capital Advisors LLC Acquires 8,113 Shares of Royalty Pharma plc (NASDAQ:RPRX)

June 10, 2025 | marketbeat.com

Wedge Capital Management L L P NC Takes Position in Royalty Pharma plc (NASDAQ:RPRX)

June 8, 2025 | marketbeat.com

Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

June 4, 2025 | globenewswire.com

Ameriprise Financial Inc. Reduces Position in Royalty Pharma plc (NASDAQ:RPRX)

June 4, 2025 | marketbeat.com

Royalty Pharma plc (NASDAQ:RPRX) On An Uptrend: Could Fundamentals Be Driving The Stock?

June 2, 2025 | finance.yahoo.com

Royalty Pharma plc (NASDAQ:RPRX) Shares Purchased by California State Teachers Retirement System

May 31, 2025 | marketbeat.com

Mackenzie Financial Corp Buys 9,313 Shares of Royalty Pharma plc (NASDAQ:RPRX)

May 31, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALNY, HZNP, BMRN, and RPRX Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$309.70 -2.62 (-0.84%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$315.00 +5.31 (+1.71%)

As of 06/20/2025 07:57 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

BioMarin Pharmaceutical NASDAQ:BMRN

$55.00 -0.24 (-0.43%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$54.93 -0.07 (-0.13%)

As of 06/20/2025 07:35 PM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Horizon Therapeutics Public NASDAQ:HZNP

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

Royalty Pharma NASDAQ:RPRX

$34.86 -0.05 (-0.14%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$34.86 +0.01 (+0.01%)

As of 06/20/2025 07:26 PM Eastern

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time